Novel unsymmetrical silicon(IV) phthalocyanines as highly potent anticancer photosensitizers. Synthesis, characterization, and in vitro photodynamic activities
Source abstract
Abstract
Abstract A series of novel unsymmetrical silicon (IV) phthalocyanines (SiPcs) di-substituted axially with tyramine and different oligomeric ethylene glycol moieties have been synthesized by alkoxy exchange reactions, and their singlet oxygen quantum yields (ΦΔ) and in vitro photodynamic activities have also been evaluated. The unsymmetrical SiPcs 2–5 show slightly higher photosensitizing efficiency (ΦΔ = 0.08–0.12) than the corresponding symmetrical SiPc 1 (ΦΔ = 0.05), but are less efficient compared to the symmetrical SiPc 6 (ΦΔ = 0.33). All the compounds exhibit high photocytotoxicities against BGC-823 cancer cells with IC50 values ranging from 3 nM to 20 nM. Particularly for the unsymmetrical SiPc 5, the IC50 value toward BGC-823 cells is significantly lower than its corresponding symmetrical SiPcs 1 and 6, which could be attributed to its higher cellular uptake. In addition, SiPc 5 can essentially bind to mitochondria and induces cell death of BGC-823 cells mainly through apoptosis. So SiPc 5 is a highly promising photosensitizer for photodynamic therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Photodynamic Therapy Research Studies · Porphyrin and Phthalocyanine Chemistry · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT10.1016/j.jphotobiol.2009.04.001 ↗
2. Photodynamic therapy for cancer10.1038/nrc1071 ↗
3. The present and future role of photodynamic therapy in cancer treatment10.1016/S1470-2045(04)01529-3 ↗
4. Current clinical and preclinical photosensitizers for use in photodynamic therapy10.1021/jm040074b ↗
5. Photodynamic therapy in oncology10.1634/theoncologist.11-9-1034 ↗
6. Targeted photodynamic therapy–a promising strategy of tumor treatment10.1039/c0pp00147c ↗
7. Phthalocyanines as medicinal photosensitizers: developments in the last five years10.1016/j.ccr.2017.08.003 ↗
8. Drug targeting strategies for photodynamic therapy10.2174/187152012800617830 ↗
9. Tumor-targeted photodynamic therapy
10. Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy10.2174/092986707780830970 ↗
11. Targeted photodynamic therapy via receptor mediated delivery systems10.1016/j.addr.2003.08.015 ↗
12. Photosensitizer-antibody conjugates for detection and therapy of cancer10.1016/j.addr.2003.09.003 ↗
13. RGD-modified albumin nanoconjugates for targeted delivery of a porphyrin photosensitizer10.1021/acs.molpharmaceut.7b00321 ↗
14. New amphiphilic silicon(IV) phthalocyanines as efficient photosensitizers for photodynamic therapy: synthesis, photophysical properties, and in vitro photodynamic activities10.1002/chem.200400462 ↗
15. A dual activatable photosensitizer toward targeted photodynamic therapy10.1021/jm500456e ↗
16. Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial10.1002/lsm.20984 ↗
17. Unsymmetrical b-cyclodextrin-conjugated silicon(IV) phthalocyanines as highly potent photosensitisers for photodynamic therapy10.1039/c1cc13783b ↗
18. Synthesis, spectroscopic and fibroblast activation protein (FAP)-responsive properties of phthalocyanine-doxorubicin conjugates
19. New phthalocyanine photosensitizers for photodynamic therapy10.1111/j.1751-1097.1993.tb02282.x ↗
20. Highly photostable silicon(IV) phthalocyanines containing adamantane moieties: synthesis, structure, and properties10.1016/j.tet.2010.09.007 ↗
21. The first silicon(IV) phthalocyanine-nucleoside conjugates with high photodynamic activity10.1039/c3dt50910a ↗
22. Novel silicon(IV) phthalocyanines containing piperidinyl moieties: synthesis and in vitro antifungal photodynamic activities10.1016/j.dyepig.2014.07.029 ↗
23. A silicon(IV) phthalocyanine-folate conjugate as an efficient photosensitizer10.1246/cl.140607 ↗
24. Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates10.1016/j.ejmech.2018.05.039 ↗
25. New application of phthalocyanine molecules: from photodynamic therapy to photothermal therapy by means of structural regulation rather than formation of aggregates10.1039/C7SC05115H ↗
26. Photodynamic inactivation of Candida albicans sensitized by a series of novel axially di-substituted silicon (IV) phthalocyanines10.1016/j.dyepig.2012.09.013 ↗
27. Highly photocytotoxic silicon(IV) phthalocyanines axially modified with L-tyrosine derivatives: effects of mode of axial substituent connection and of formulation on photodynamic activity10.1016/j.dyepig.2017.03.004 ↗
28. Synthesis, properties, and photodynamic inactivation of Escherichia coli using a cationic and a noncharged Zn (II) pyridyloxyphthalocyanine derivatives10.1016/j.bmc.2005.01.063 ↗
29. Silicon octaphenoxyphthalocyanines: photostability and singlet oxygen quantum yields10.1016/S1010-6030(01)00409-9 ↗
30. Influence of surfactants on the aggregation behavior of water-soluble dendritic phthalocyanines10.1021/ma9919110 ↗
31. Mitochondria-based photodynamic anti-cancer therapy10.1016/S0169-409X(01)00126-0 ↗
32. Cell death pathways in photodynamic therapy of cancer10.3390/cancers3022516 ↗
33. Silicon(IV) phthalocyanines substituted axially with different nucleoside moieties. Effects of nucleoside type on the photosensitizing efficiencies and in vitro photodynamic activities10.1016/j.jphotobiol.2016.03.055 ↗
34. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V10.1016/0022-1759(95)00072-I ↗
35. Synthesis and antifungal photodynamic activities of a series of novel zinc(II) phthalocyanines substituted with piperazinyl moieties10.1016/j.dyepig.2013.04.032 ↗